Seeking Alpha


Send Message
View as an RSS Feed
View vladsaar's Comments BY TICKER:
Latest  |  Highest rated
  • A Quick Look At 2 Small-Cap Bio-Pharmaceutical Companies: Discovery Labs And Exelixis [View article]
    Well, thank you doc. You bring up all the valued points that are currently the very subject of the FDA approved study(ies). One point to make concerning your example of albuterol versos aerosolized surfactant combined with nCPAP is that the later finding suggests that with aerosolized surfactant there is no need to aim the terminal airways as the final target for delivery. The ability of surfactants to spread along mucosal surfaces can lead to improved lung deposition and more uniform drug distribution. The main effort, as it seems, is concentrated around the surfactan's optimal particle size, viscosity and dosage (which is what Aerosurf device is adopted to optimize) to achieve the desired effect and thus reach the most hard to get parts of the lugs. Besides many prior animal test (rabbits and lambs) had shown a rather increased efficacy of aerosolized surfactants in improving lungs functions. Thank you for the input.
    Aug 4, 2014. 09:37 AM | Likes Like |Link to Comment
  • A Quick Look At 2 Small-Cap Bio-Pharmaceutical Companies: Discovery Labs And Exelixis [View article]
    Cuttail07, sorry if you've detected some rudeness in my comment which came in response to your initial expression of doubt despite your admitting that "I am relatively unfamiliar with DSCO and its product line." I did not attack opinions, I pointed out that in order to have one you need to be familiar with the product line and principles of operation of the subject device. Calling it a mere "asthma inhaler" as the author did is grossly misleading. Now after reading the Smith's in depth comment you changed your opinion saying that in case it works - "..this would become a very valuable medication in that field." (!!!?) Again, Aerosurf is a drug-device product combination which is built around specific qualities of KL4 surfactant suitable to be delivered in aerosolized form combined with nCPAP procedure thus replacing the need of mechanical ventilation and INTUBATION! Yours and the author's initial message was that intubation will always be necessary quote - " Patients who are sick enough to need surfactant will likely need to be intubated anyway" I find this claim misleading and wrong! I do not claim that AEROSURF is a done deal thus all the studies, NIH, backed by $2.5M grant, thinks it is worth it. You should admit that in case AEROSURF works it will be revolutionary despite the cost in comparison with intubation (see Smith's calculations above that shows that it might even be a serious cost saver) as it may replace dangerous intubation all together. You are right though it remains to be seen. I would much appreciate your opinion as a medical doctor as to what hurdles would DSCO need to overcome in order to make this device work. Finally I call in doubt the author's intention to convey his holding position now when the stock is at 52 week low only days to PH2a data release. Nothing has changed as far as his understanding (or misunderstanding) of the DSCO products is concerned since the Q1 report in March. Thank you very much. And sorry for a "rude" tone!
    Aug 3, 2014. 04:35 PM | Likes Like |Link to Comment
  • A Quick Look At 2 Small-Cap Bio-Pharmaceutical Companies: Discovery Labs And Exelixis [View article]
    I urge SA to remove this article at least in that portion concerning Discovery Lab. as highly misleading and false! It is abundantly obvious that the author does not understand the first thing about Aerosurf principle of operation - it comes to replace intubation all together not either/or! It either works and replaces intubation or there is no Aerosurf!
    Aug 2, 2014. 08:51 PM | 2 Likes Like |Link to Comment
  • A Quick Look At 2 Small-Cap Bio-Pharmaceutical Companies: Discovery Labs And Exelixis [View article]
    I am not a medical professional, but nevertheless would strongly disagree with the above blatant statements based on "feelings" as far as potential efficacy of the DSCO's Aerosurf is concerned. What you have state above is highly misleading and damaging! Further the opinion of Cuttail07, who claims to be a MD, is most amazing and short sighted. You both, Gentlemen, fail, quite deliberately as it appears, to mention the core essence of AEROSURF drug-device product combination and what might if successful become a really life saving revolutionary device.
    Your statement that - "Unlike other surfactants that require a tube to be put down the patient's throat, this medication can be given as an aerosol -- like an asthma inhaler. They claim this has the potential to revolutionize the treatment of respiratory distress syndrome. I have serious doubts. Patients who are sick enough to need surfactant will likely need to be intubated anyway" is a complete FALSITY!!!! This is nothing like ASTHMA INHALER !!!
    In fact large number of premature infants with RDS can not be intubated as this is highly invasive and potentially dangerous procedure. To avoid severe complications neonatologists generally attempt to provide respiratory support to neonates using less invasive means, such as nasal continuous positive airway pressure (nCPAP), and consequently will not treat infants who could benefit from surfactant therapy unless they determine that the potential benefits of surfactant therapy outweigh the risks associated with endotracheal intubation and mechanical ventilation. Unfortunately in many cases premature babies do not respond to only nCPAP (condition that is not known ahead of using nCPAP) thus intubation with surfactant is required after all resulting is loss of critical time!

    AEROSURF® potentially will provide practitioners with the ability to deliver surfactant therapy to premature infants supported with nCPAP REPLACING INTUBATION, saving time and many premature babies lives that currently are neither intubated, nor respond to nCPAP without surfactant!!!! THIS IS REVOLUTIONARY and live saving of many tens of thousands of babies.

    In fact this drug-device product is so important and promising that NIH (National Institute of Health) had granted DSCO a $2.5 million grant to conduct Phase 2 study currently under way with tolerability data to out shortly.
    Why you choose to write such a misleading article is beyond conventional logic!
    Aug 2, 2014. 08:35 PM | 1 Like Like |Link to Comment
  • Zack's likes Rosetta Genomics [View news story]
    #ROSG agrees w/ @Carl_C_Icahn & think that gene expression profiling & "Genetics.. going to be the major the world..& in science"
    Mar 6, 2014. 11:15 AM | Likes Like |Link to Comment
  • Velti (VELT -2.9%) files an F-3 to sell 16.5M shares on behalf of insiders. The filing comes with shares of the mobile ad agency down 56% YTD, and down 81% over the last 12 months. (Q1/2013 guidance) Update: As commenter James Sands points out, the shares will be sold by accredited investors who recently purchased them from Velti at $1.50/share (25% below Velti's current price) through a private placement. [View news story]
    Why such an anti-shareholders "private placement" without a lockup clause even? This is a criminal insiders deal to fleece unsuspected and long suffering from a totally inept management retail investor. That genus CFO Mr. Ross must be a greatest lairs first destroying the stock price by talking BS and having the stock plunge from $6 to $2 and making a final killing by selling a bunch of shares at $1.5 so that the fat cats could line up their pockets with quick 33% profit? Why, couldn't he use ATM at much betters price, ah? Or this POS VELTI is about to go belly up thanks to Mr. Mauskas a pathological lair! The worst thing is that as usual the earnings report's results have been long leaked to the WS crooks and insiders, thus all this pressure and profit taking on our backs! Ross and Mauskas, Let the wrath of God fall upon you!
    May 7, 2013. 02:03 PM | 1 Like Like |Link to Comment